Caregivers
Caring for yourself is one of the most important things you can do as a caregiver. Unfortunately, it is often neglected.
Caring for yourself is one of the most important things you can do as a caregiver. Unfortunately, it is often neglected.
Caregivers play an important role in supporting their loved one at every stage of the colorectal cancer journey. But who supports the caregiver?
As a caregiver, your resources will be essential. We have gathered a collection that will help.
Acting as someone's caregiver make you feel like a nurse, parent, or maid. It’s normal to have strong emotions about your new role.
As the needs and symptoms of the cancer patient fluctuate, so do the needs and well-being of the caregiver.
Caregivers field a lot of information and it can become overwhelming. Learn how you can stay on top of things.
It’s important to know what to ask at doctor's visit, especially as a caregiver. Don't forget to bring a notebook and pen.
Caregivers communicate across many channels from the patient to the doctors to insurance companies.
Many caregivers take time off from work to take care of loved ones, which can create a financial strain.
Caregiving is often a long-term challenge and the emotional impact can mount over time. It's important to recognize the signs of burnout.
When a loved one dies, the loss as a caregiver may be mixed with guilt, relief, and uncertainty over the future.
Sometimes you just need to talk to someone. We are here for you at all times –just give us a call on our Toll Free Helpline (877) 422-2030.
Wearing the badge of ‘caregiver’ presents unique challenges. The greatest one may be learning how to take care of yourself.
Michelle Cappel owes a lot to colorectal cancer biomarker testing — seven years of life and counting.
Don Shippey was 55 years old in 2016 when he decided he’d been putting off his colonoscopy long enough.
Takeda has announced U.S. Food and Drug Administration (FDA) approval of FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.